About this trial
People living in NH are at higher risk of respiratory infections compared to their counterpart living in the community. Products obtained from dead bacteria ("bacterial lysate") can be used to boost immune system and may reduce the risk of respiratory infections. Very little information is available on the effect of these substances in older people. This study will evaluate the efficacy of a bacterial lysate in reducing the incidence of lower respiratory tract infections in older people living in nursing homes. The study will include a treatment arm, in which participants will received the lysate, and a control arm in which participants will received a matching placebo (i.e., a pill that has the same appearance of the lysate but does not contain the lysate itself).
Eligibility criteria
Qualifiers
Age 75 years or older
At least 2 RTIs in the year prior to enrollment
Patients must have been residing in nursing homes for at least 6 months and have an estimated length of stay in nursing homes of at least 6 months by their treating physician.
Signed informed consent. If participants are unable to provide informed consent due to cognitive impairment, consent will be provided by a legally recognized representative or trustee of the patient (pursuant to Article 4 of Law No. 219 of December 22, 2017).
Disqualifiers
Patients with known allergy or previous intolerance to any component (including the excipient) of the study drug
Patients with active neoplasia and prognosis of less than one year
Patients with previous organ transplantation
Patients treated with prohibited drugs (see Table 1) in the 3 months prior to the start of the study
Trial design
Treatments tested in this trial
- Bacterial Lysate
- Placebo
Treatment groups
Sponsors and collaborators
Campus Bio-Medico University
Lead sponsor
OM Pharma SA
Collaborator